GENSIGHT BIOLOGICS news, videos and press releases
For more news please use our advanced search feature.
GENSIGHT BIOLOGICS - More news...
GENSIGHT BIOLOGICS - More news...
- GenSight Biologics announces a financing for an amount of c. €1.5 million from existing investors
- GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
- GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
- GenSight Biologics Obtains Funding of €10 Million From Sofinnova Partners, Invus and UPMC Enterprises
- GenSight Biologics Provides Financial and Operational Update
- GenSight Biologics: Annual General Meeting on June 21, 2023
- GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023
- GenSight Biologics Announces the Re-approval of its Full Year 2022 Consolidated Financial Statements
- GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update
- GenSight Biologics Withdraws its EMA Application for LUMEVOQ®
- GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings
- GenSight Biologics Reports Full Year 2022 Consolidated Financial Results
- GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
- GenSight Biologics to Present at Upcoming Medical Conferences
- GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
- GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines
- GenSight Biologics Announces its 2023 Financial Calendar
- Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)
- GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
- GenSight Biologics Announces the Drawdown of the First EUR 8 Million Tranche Under Its Credit Agreement With the European Investment Bank
- GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update
- GenSight Biologics to Present at Upcoming Investor Conferences
- GenSight Biologics Secures €12 Million Financing Through a Premium Convertible Notes Issuance to an Institutional Investor and Provides Business Update
- GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
- GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals
- GenSight Biologics Secures a €35 Million Credit Facility From the European Investment Bank to Support the Launch of LUMEVOQ® in Europe
- GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022
- GenSight Biologics to Present at Upcoming 2022 Medical Conferences
- GenSight Biologics to Present at Upcoming Industry and Investor Conferences
